TIL-ACT is based on the concept that the cellular immune response to cancer largely depends on conventional T cells, CD8+ and CD4+, that specifically target tumor-specific antigens such as cancer/testis antigens or cancer neoantigens (NeoAgs) that are derived from somatic genomic alterations that lead to the expression of immunogenic neo-epitopes.28, , –31. This evidence concerns the gene CD8A and cancer.